Incyte (INCY) Competitors $64.78 -0.52 (-0.80%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$64.83 +0.05 (+0.08%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INCY vs. ALNY, BIIB, UTHR, NBIX, BMRN, EXEL, EXAS, HALO, RGEN, and MDGLShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Repligen (RGEN), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Incyte vs. Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Exact Sciences Halozyme Therapeutics Repligen Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Do analysts prefer ALNY or INCY? Alnylam Pharmaceuticals currently has a consensus target price of $319.17, indicating a potential upside of 9.09%. Incyte has a consensus target price of $73.53, indicating a potential upside of 13.51%. Given Incyte's higher possible upside, analysts clearly believe Incyte is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77Incyte 1 Sell rating(s) 13 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.17 Which has higher valuation and earnings, ALNY or INCY? Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.35B16.25-$278.16M-$2.09-139.99Incyte$4.41B2.84$32.62M$0.32202.44 Does the media favor ALNY or INCY? In the previous week, Incyte had 6 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 27 mentions for Incyte and 21 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.33 beat Incyte's score of 1.11 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 15 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 22 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ALNY or INCY more profitable? Incyte has a net margin of 0.77% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Incyte's return on equity of 0.05% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% Incyte 0.77%0.05%0.04% Does the MarketBeat Community prefer ALNY or INCY? Incyte received 60 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.32% of users gave Alnylam Pharmaceuticals an outperform vote while only 72.22% of users gave Incyte an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes116776.32% Underperform Votes36223.68% IncyteOutperform Votes122772.22% Underperform Votes47227.78% Which has more risk and volatility, ALNY or INCY? Alnylam Pharmaceuticals has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Do institutionals & insiders hold more shares of ALNY or INCY? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 17.8% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryIncyte beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteCommercial physical research IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.54B$3.00B$5.37B$8.39BDividend YieldN/A2.27%5.22%4.10%P/E Ratio239.93109.8026.7719.71Price / Sales2.84162.05393.17117.39Price / Cash128.9434.5738.2534.62Price / Book3.642.356.794.50Net Income$32.62M$118.81M$3.23B$248.18M7 Day Performance3.22%-3.41%1.53%0.20%1 Month Performance12.90%-3.43%10.06%12.37%1 Year Performance11.31%-17.71%16.74%7.04% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.8757 of 5 stars$64.78-0.8%$73.53+13.5%+12.9%$12.54B$4.41B239.932,320Positive NewsALNYAlnylam Pharmaceuticals3.6617 of 5 stars$270.19+7.6%$319.17+18.1%+95.5%$35.23B$2.35B-124.512,000Positive NewsBIIBBiogen4.8992 of 5 stars$124.40+5.3%$191.30+53.8%-44.3%$18.23B$9.82B11.128,720Analyst RevisionUTHRUnited Therapeutics4.9788 of 5 stars$310.80+3.1%$392.00+26.1%+12.5%$14.02B$2.99B13.65980Positive NewsNBIXNeurocrine Biosciences4.9182 of 5 stars$120.43+4.1%$162.00+34.5%-14.2%$11.92B$2.41B36.601,200Positive NewsBMRNBioMarin Pharmaceutical4.9462 of 5 stars$61.37+4.3%$93.45+52.3%-24.4%$11.77B$2.95B27.903,080Positive NewsInsider TradeEXELExelixis4.1194 of 5 stars$36.98+2.2%$37.59+1.6%+108.0%$10.19B$2.17B20.891,220EXASExact Sciences4.2852 of 5 stars$53.40+3.4%$70.90+32.8%+6.3%$10.07B$2.83B-9.596,400Positive NewsHALOHalozyme Therapeutics4.8553 of 5 stars$66.58+1.1%$63.78-4.2%+18.4%$8.20B$1.08B19.41390RGENRepligen4.8235 of 5 stars$133.72+8.5%$173.25+29.6%-28.0%$7.51B$650.43M-262.202,020Positive NewsGap UpMDGLMadrigal Pharmaceuticals4.5986 of 5 stars$300.76+2.1%$416.33+38.4%+14.3%$6.68B$317.38M-11.9990Positive News Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors BioMarin Pharmaceutical Competitors Exelixis Competitors Exact Sciences Competitors Halozyme Therapeutics Competitors Repligen Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCY) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INCY Stock Free INCY Stock Alerts